Literature DB >> 23222156

Mechanisms of sustained signalling in asthma.

Christina A Christianson1, Rafeul Alam.   

Abstract

PURPOSE OF REVIEW: The role of immunological memory formation focusing upon Th2 inflammatory responses in asthma is well supported and reviewed previously. Here, we review data supporting the establishment of a tissue-based signalling memory utilizing examples of in-vitro, in-vivo and clinical reports of sustained extracellular signal regulated kinase 1/2 (ERK1/2) activation in asthma. RECENT
FINDINGS: Endosomal recycling of receptors contributes to chronic signalling activation, presumably through increased receptor availability. This chronic signalling constitutes a bistable state and the formation of a tissue memory. The transition to chronic asthma is marked by the persistence of low-level disease severity and chronic signalling in the apparent absence of an environmental trigger.
SUMMARY: System bistability provides a mathematical explanation for a tissue-based memory. We will have to generate quantitative data about the involved biochemical reactions (substrates, products, dissociation constants of the reactions) to utilize this model. Only then will we be able to understand and interfere with a tissue memory-driven disease and curtail the persistence of asthma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23222156     DOI: 10.1097/ACI.0b013e32835c168e

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  1 in total

1.  Inhibition of MAPK and STAT3-SOCS3 by Sakuranetin Attenuated Chronic Allergic Airway Inflammation in Mice.

Authors:  Fernanda P R Santana; Rafael C da Silva; Simone Dos S Grecco; Aruanã J M C R Pinheiro; Luciana C Caperuto; Fernanda M Arantes-Costa; Samuel R Claudio; Kelly Yoshizaki; Mariângela Macchione; Daniel A Ribeiro; Iolanda F L C Tibério; Lídio G Lima-Neto; João H G Lago; Carla M Prado
Journal:  Mediators Inflamm       Date:  2019-09-03       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.